{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T01:22:49Z","timestamp":1776734569473,"version":"3.51.2"},"reference-count":46,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1016\/j.jbspin.2009.12.002","type":"journal-article","created":{"date-parts":[[2010,1,27]],"date-time":"2010-01-27T08:44:41Z","timestamp":1264581881000},"page":"120-124","source":"Crossref","is-referenced-by-count":22,"title":["Monoclonal gammopathy of undetermined significance, multiple myeloma, and osteoporosis"],"prefix":"10.1016","volume":"77","author":[{"given":"B\u00e9atrice","family":"Bouvard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathieu","family":"Royer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Chappard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurice","family":"Audran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Hopp\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erick","family":"Legrand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2009.12.002_bib1","doi-asserted-by":"crossref","unstructured":"The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working group. Br J Haematol 2003;121:749-57.","DOI":"10.1046\/j.1365-2141.2003.04355.x"},{"key":"10.1016\/j.jbspin.2009.12.002_bib2","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2009.12.002_bib3","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A long-term study of prognosis in monoclonal gammopathy of undetermined significance","volume":"346","author":"Kyle","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2009.12.002_bib4","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.blre.2007.01.002","article-title":"Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma","volume":"21","author":"Rajkumar","year":"2007","journal-title":"Blood Rev"},{"key":"10.1016\/j.jbspin.2009.12.002_bib5","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2009.12.002_bib6","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","article-title":"Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jbspin.2009.12.002_bib7","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1182\/blood-2002-09-2684","article-title":"RANK ligand and osteoprotegerin in myeloma bone disease","volume":"101","author":"Sezer","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jbspin.2009.12.002_bib8","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1182\/blood.V100.6.2195","article-title":"Role for macrophage inflammatory protein (MIP)-1\u03b1 and MIP-1\u03b2 in the development of osteolytic lesions in multiple myeloma","volume":"100","author":"Abe","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jbspin.2009.12.002_bib9","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1182\/blood-2002-08-2383","article-title":"Macrophage inflammatory 1-alpha (MIP-1\u03b1) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells","volume":"101","author":"Lentzsch","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jbspin.2009.12.002_bib10","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1046\/j.1365-2141.2003.04561.x","article-title":"A. Serum levels of macrophage inflammatory protein 1-alpha (MIP-1\u03b1) correlate with the extent of bone disease and survival in patients with multiple myeloma","volume":"123","author":"Tepos","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jbspin.2009.12.002_bib11","doi-asserted-by":"crossref","first-page":"6973","DOI":"10.1158\/1078-0432.CCR-06-0323","article-title":"Tumor angiogenesis is associated with plasma levels of stromal-derived factor 1\u03b1 in patients with multiple myeloma","volume":"12","author":"Martin","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jbspin.2009.12.002_bib12","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1093\/annonc\/mdi235","article-title":"Myeloma bone disease: pathophysiology and management","volume":"16","author":"Terpos","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jbspin.2009.12.002_bib13","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.exphem.2006.06.017","article-title":"Chemokines in multiple myeloma","volume":"34","author":"Aggarwal","year":"2006","journal-title":"Exp Hematol"},{"key":"10.1016\/j.jbspin.2009.12.002_bib14","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa030847","article-title":"The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma","volume":"349","author":"Tian","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2009.12.002_bib15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2141.2007.06871.x","article-title":"Myeloma cell expression of 10 candidate genes for osteolytic bone disease. Only overexpression of DKK1 correlates with clinical bone involvement at diagnosis","volume":"140","author":"Haaber","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jbspin.2009.12.002_bib16","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood-2006-09-047712","article-title":"Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo","volume":"109","author":"Yaccoby","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jbspin.2009.12.002_bib17","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/j.1365-2141.2006.06356.x","article-title":"Bortezomib reduces serum dickkopf-1 and receptor nuclear factor-kB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma","volume":"135","author":"Terpos","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jbspin.2009.12.002_bib18","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1182\/blood-2004-12-4940","article-title":"Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2","volume":"106","author":"Oshima","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jbspin.2009.12.002_bib19","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1182\/blood-2006-05-026112","article-title":"Multiple myeloma bone disease: pathophysiology of osteoblast inhibition","volume":"108","author":"Giuliani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jbspin.2009.12.002_bib20","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1096\/fj.05-4329fje","article-title":"A role of TRAIL in killing osteoblasts by myeloma cells","volume":"20","author":"Tinhofer","year":"2006","journal-title":"FASEB J"},{"key":"10.1016\/j.jbspin.2009.12.002_bib21","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1182\/blood-2005-03-1080","article-title":"IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma","volume":"106","author":"Ehrlich","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jbspin.2009.12.002_bib22","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1182\/blood-2003-06-1992","article-title":"IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells","volume":"103","author":"Lee","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jbspin.2009.12.002_bib23","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1182\/blood-2005-07-2719","article-title":"Interleukin-3 (IL-3) is overexpressed by T lymphocytes in multiple myeloma patients","volume":"107","author":"Giuliani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jbspin.2009.12.002_bib24","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1600-0609.1994.tb01327.x","article-title":"Dual energy X-ray absorptiometry measurements of bone mineral density in myeloma","volume":"53","author":"Holmes","year":"1994","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jbspin.2009.12.002_bib25","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1600-0609.1996.tb01395.x","article-title":"Assessment of bone involvement in patients with multiple myeloma using bone densitometry","volume":"57","author":"Abildgaard","year":"1996","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jbspin.2009.12.002_bib26","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3109\/10428199809059252","article-title":"B. Biologic and therapeutic determinants of bone mineral density in multiple myeloma","volume":"32","author":"Dhodapkar","year":"1998","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jbspin.2009.12.002_bib27","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/0002-9343(92)90190-M","article-title":"Bone densitometry in patients with multiple myeloma","volume":"93","author":"Mariette","year":"1992","journal-title":"Am J Med"},{"key":"10.1016\/j.jbspin.2009.12.002_bib28","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/1097-0142(19951101)76:9<1559::AID-CNCR2820760910>3.0.CO;2-R","article-title":"Evaluation of bone densitometry in patients with myeloma treated with conventional or intensive therapy","volume":"76","author":"Mariette","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.jbspin.2009.12.002_bib29","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1359\/JBMR.041131","article-title":"Fracture risk with multiple myeloma: a population-based study","volume":"20","author":"Melton","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jbspin.2009.12.002_bib30","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.blre.2004.06.001","article-title":"The role of markers of bone remodeling in multiple myeloma","volume":"19","author":"Terpos","year":"2005","journal-title":"Blood Rev"},{"key":"10.1016\/j.jbspin.2009.12.002_bib31","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/ijc.11247","article-title":"Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma","volume":"106","author":"Terpos","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jbspin.2009.12.002_bib32","first-page":"3047","article-title":"Serum levels of carboxy-terminal telopeptide of type-I collagen are elevated in patients with multiple myeloma showing skeletal manifestations in magnetic resonance imaging but lacking lytic bone lesions in conventional radiography","volume":"9","author":"Jakob","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"Suppl 1","key":"10.1016\/j.jbspin.2009.12.002_bib33","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0305-7372(06)80004-6","article-title":"Biochemical markers of bone metabolism in multiple myeloma","volume":"32","author":"Terpos","year":"2006","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jbspin.2009.12.002_bib34","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/bmj.38376.401701.8F","article-title":"Utility of testing for monoclonal bands in serum of patients with suspected osteoporosis: retrospective, cross sectional study","volume":"330","author":"Abrahamsen","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.jbspin.2009.12.002_bib35","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s00198-007-0525-7","article-title":"Secondary contributors to bone loss in osteoporosis related hip fractures","volume":"19","author":"Edwards","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jbspin.2009.12.002_bib36","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1365-2141.2006.06217.x","article-title":"Lumbar bone mineral density as the major factor determining increased prevalence of vertebral fractures in monoclonal gammopathy of undetermined significance","volume":"134","author":"Pepe","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jbspin.2009.12.002_bib37","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1359\/jbmr.0301212","article-title":"Fracture risk in monoclonal gammopathy of undetermined significance","volume":"19","author":"Melton","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jbspin.2009.12.002_bib38","first-page":"717","article-title":"Apport de la biopsie osseuse avec histomorphom\u00e9trie dans l\u2019\u00e9valuation d\u2019une gammapathie monoclonale","volume":"54","author":"Alexandre","year":"1987","journal-title":"Rev Rhum"},{"key":"10.1016\/j.jbspin.2009.12.002_bib39","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1182\/blood.V87.11.4762.bloodjournal87114762","article-title":"Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: a prospective study of 87 bone biopsies","volume":"87","author":"Bataille","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.jbspin.2009.12.002_bib40","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1172\/JCI115305","article-title":"Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma","volume":"88","author":"Bataille","year":"1991","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jbspin.2009.12.002_bib41","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/cncr.23783","article-title":"A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma","volume":"113","author":"Musto","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.jbspin.2009.12.002_bib42","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1046\/j.1365-2141.2002.03549.x","article-title":"Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti-tumour effect","volume":"118","author":"Martin","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jbspin.2009.12.002_bib43","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1200\/JCO.2003.99.248","article-title":"Pamidronate for early-stage, untreated myeloma","volume":"21","author":"Musto","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jbspin.2009.12.002_bib44","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1080\/1042819031000099715","article-title":"Pamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: results of a randomized trial","volume":"44","author":"Musto","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jbspin.2009.12.002_bib45","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s00223-008-9145-2","article-title":"The effects of alendronate treatment in osteoporotic patients affected by monoclonal gammopathy of undetermined significance","volume":"82","author":"Pepe","year":"2008","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.jbspin.2009.12.002_bib46","doi-asserted-by":"crossref","first-page":"6289","DOI":"10.1158\/1078-0432.CCR-08-0666","article-title":"Zoledronic acid markedly improves bone mineral density for patients with monoclonal gammopathy of undetermined significance and bone loss","volume":"14","author":"Berenson","year":"2008","journal-title":"Clin Cancer Res"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X09002449?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X09002449?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T05:10:37Z","timestamp":1711170637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X09002449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S1297319X09002449"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2009.12.002","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}